Loading
A phase 1/2 trial of intravenous (IV) infusion in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
A Clinical Study of YL205 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06459973 by MediLink Therapeutics (Suzhou) Co., Ltd., with 252 participants planned, started 2024-06-04 and due to reach its primary completion in 2027-07-31. Interventions recorded: intravenous (IV) infusion.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/